%0 Journal Article
%A Menzer, Christian
%A Menzies, Alexander M
%A Carlino, Matteo S
%A Reijers, Irene
%A Groen, Emma J
%A Eigentler, Thomas
%A de Groot, Jan Willem B
%A van der Veldt, Astrid A M
%A Johnson, Douglas B
%A Meiss, Frank
%A Schlaak, Max
%A Schilling, Bastian
%A Westgeest, Hans M
%A Gutzmer, Ralf
%A Pföhler, Claudia
%A Meier, Friedegund
%A Zimmer, Lisa
%A Suijkerbuijk, Karijn P M
%A Haalck, Thomas
%A Thoms, Kai-Martin
%A Herbschleb, Karin
%A Leichsenring, Jonas
%A Menzer, Alexander
%A Kopp-Schneider, Annette
%A Long, Georgina V
%A Kefford, Richard
%A Enk, Alexander
%A Blank, Christian U
%A Hassel, Jessica C
%T Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
%J Journal of clinical oncology
%V 37
%N 33
%@ 1527-7755
%C Alexandria, Va.
%I American Society of Clinical Oncology
%M DKFZ-2019-02337
%P 3142-3151
%D 2019
%Z 37(33):3142-3151
%X BRAF/MEK inhibition is a standard of care for patients with BRAF V600E/K-mutated metastatic melanoma. For patients with less frequent BRAF mutations, however, efficacy data are limited.In the current study, 103 patients with metastatic melanoma with rare, activating non-V600E/K BRAF mutations that were treated with either a BRAF inhibitor (BRAFi), MEK inhibitor (MEKi), or the combination were included. BRAF mutation, patient and disease characteristics, response, and survival data were analyzed.Fifty-eight patient tumors (56
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31580757
%R 10.1200/JCO.19.00489
%U https://inrepo02.dkfz.de/record/147211